Market Research Report: Auransa Inc.

1. Company Overview

Name: Auransa Inc.

Mission: Auransa is committed to harnessing AI and human disease data to discover novel therapeutics and raise the standard of cancer care.

Founded: No information available on the exact founding date.

Founders: Co-founder and CEO, Pek Lum, PhD; Co-founder and COO, Viwat Visuthikraisee, PhD.

Key People in the Company:

Pek Lum, PhD: Co-founder and CEO.

Viwat Visuthikraisee, PhD: Co-founder and COO.

Greg Luedtke, PhD: Chief Scientific Officer.

Headquarters: No information is available.

Number of Employees: No information is available.

Revenue: No information is available.

Known For: Auransa is recognized for its AI-native, biology-first approach to developing novel therapeutics aimed at enhancing cancer care standards.

2. Products

2.1 AU-409 for Liver Cancer

Type: Novel, first-in-class compound.

Status: Phase 1 clinical trials.

Key Features:

Aimed at treating liver cancer, one of the fastest-growing types of cancer in the US and EU, with high prevalence in Asia.

2.2 AU-018 for Heart-Safe Chemotherapy

Type: Heart-safe chemotherapy compound.

Status: IND enabling phase.

Key Features:

Targets the $1 billion anthracycline chemotherapy market.

Designed to improve tolerability for patients and raise cancer care standards.

Other Products: No additional products are detailed.

3. Recent Developments

AU-409 Clinical Trials:

August 7, 2024: First patient in Asia received AU-409 in ongoing clinical trials, extending trials beyond the US.

Innovations and Recognitions:

September 27, 2023: Auransa recognized in the Clarivate Companies to Watch Report for innovations in AI and machine learning for life sciences.

September 14, 2023: Successful first patient dosed in the Phase 1 clinical trial for liver cancer in the US.

Partnerships:

With Roche Genentech:

Collaboration to discover novel treatments for gastrointestinal toxicities.

With POLARISqb:

Research collaboration integrating AI and quantum computing to find treatments for women's diseases, such as ovarian and triple-negative breast cancer.

With USC Norris Cancer Center:

Running the US Phase 1 trial of AU-409 for advanced liver cancer along with other tumors that metastasize to the liver.

With Lee's Pharm:

Working towards clinical developments in China for AU-018 and AU-409.

New Product Launches: No information available on new product launches beside the AU-409 and AU-018 currently in trials.

New Features for Existing Products: No information available on new features for existing products.

Conclusion

Auransa Inc. stands at the forefront of integrating AI with biological research to introduce new therapeutic advancements in oncology. Their partnerships with renowned pharmaceutical and academic institutions highlight a proactive approach toward improving cancer treatment standards globally. However, several details, such as specific financial metrics or workforce data, remain undisclosed.

auransa